Liquid biopsy heralds a revolution in the management of cancer, but it is limited by the key challenge of low input levels of cell free DNA (cfDNA).
BIOCAPTIVA are developing technology, the BIOCOLLECTOR, which will be transformational for liquid biopsy testing. Providing up to 100 times more cfDNA than a venous blood draw, it will open new avenues for more comprehensive genome analysis and more precise and enhanced clinical decisions particularly for early detection of cancer thereby unlocking the potential of liquid biopsy.
BIOCAPTIVA are developing technology, the BIOCOLLECTOR, which will be transformational for liquid biopsy testing. Providing up to 100 times more cfDNA than a venous blood draw, it will open new avenues for more comprehensive genome analysis and more precise and enhanced clinical decisions particularly for early detection of cancer thereby unlocking the potential of liquid biopsy.
Location: Scotland
Employees: 1-10
Total raised: $4.77M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 17.07.2021 | Archangels | archangels... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.03.2026 | - | $2.13M | - |
| 01.06.2022 | Seed | $2.64M | - |
Mentions in press and media 5
| Date | Title | Description |
| 10.03.2026 | Biocaptiva Secures £1.58M, Unveils Pioneering Liquid Biopsy Tech in US | Biocaptiva, an Edinburgh biotech firm, secured £1.58M in new funding. They launched their innovative msX magnetic bead technology in the US. This platform extracts cell-free DNA directly from whole blood. It eliminates traditional liquid bi... |
| 09.03.2026 | Biocaptiva Raises £1.58M in New Funding | Biocaptiva, an Edinburgh, Scotland, UK-based magnetic bead technology company, raised £1.58M in new funding. The round was led by Archangels, with support from Old College Capital, BBI, Scottish Enterprise, and new investor EverQuest Capita... |
| 09.03.2026 | University of Edinburgh biotech spin-out BIOCAPTIVA raises £1.58M | University of Edinburgh spin-out BIOCAPTIVA has raised £1.58 million in a new funding round and launched its first product in the US. BIOCAPTIVA’s novel magnetic bead technology is designed to solve one of liquid biopsy’s biggest bottleneck... |
| 01.06.2022 | Biocaptiva Raises £2.1M in Additional Seed Funding | Biocaptiva Ltd, an Edinburgh, Scotland-based company developing a cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management, raised £2.1m in additional seed funding. The round was led by existing... |
| - | BioCaptiva | “BIOCAPTIVA” |